South African hypertension guideline 2011

South African Medical Journal

Volumn 102, Issue 1, 2012, Pages 60-83

  Seedat, Y K ^a   Rayner, B L ^b  

^a DURBAN UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ERGOT ALKALOID; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SOUTH AFRICA; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; PRACTICE GUIDELINE;

HUMANS; HYPERTENSION;

EID: 84255169913     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Southern African Hypertension Society. Guidelines for the management of hypertension at primary health care level. S Afr Med J 1995;85:1321-1325.
2. Southern African Hypertension Society. Hypertension Clinical Guideline 2000. S Afr Med J 2001;91:163-172.
3. Milne PJ, Pinkney-Atkinson VJ. Southern African Society Hypertension Guideline Working Groups 2000 and 2003. S Afr Med J 2004;94:209-216.
4. Seedat YK, Croasdale MA, Milne FJ, et al. South African Hypertension Guideline 2006. S Afr Med J 2006;96:337-362.
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Conference on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-2572.
6. Harkam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendation for the management of hypertension: Part 2 - therapy. Can J Cardiol 2010;26:249-258.
7. Mancia G, Laurent S, Agahiti-Rosei, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens 2009;27:2121-2158.
8. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992.
9. Williams B, Poulter WB, Brown MJU, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J Hum Hypertens 2004;18:139-185.
10. National Clinical Guideline Centre. Hypertension: The clinical management of primary hypertension in adults. London: National Institute for Health and Clinical Excellence. http://www.nice.org.uk/nicemedia/live/12167/54727/54727.pdf (accessed 20 October 2011).
11. Steyn K, Gaziano T, Bradshaw D, et al. Hypertension in South African adults: results from the Demographic and Health Report 1998. J Hypertens 2001;19:1717-1725.
12. Bradshaw D, Groenewald P, Laubscher R, et al. Initial burden of disease estimates for South Africa, 2000. S Afr Med J 2003;93:682-688.
13. Kearney PM, Whelton M, Reynolds, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223.
14. World Health Organization. Integrated management of cardiovascular risk. Geneva: WHO, 2002. http://whqlibdoc.who.int/publications/9241562242.pdf (accessed 20 October 2011).
15. Pestana JAX, Steyn K, Leiman A, Hartzenberg GM. The direct and indirect costs of cardiovascular disease in South Africa. S Afr Med J 1996;86:679-684.
16. Dougherty J, McIntyre D, Bloom G. Value for money in South African health care: findings of a review of health expenditure and finance. Cent Afr J Med 1996;42:21-24.
17. World Health Organization. CVD - Risk Management Package for Low and Medium- Resource Settings. Geneva: WHO, 2002. http://www.who.int/cardiovascular_diseases/publications/cvd_package2002/en/index.html (accessed 20 October 2011).
18. O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for conventional, ambulatory and home blood pressure measurement. J Hypertens 2005;23:697-701.
19. Rosenthal T. Seasonal variations in blood pressure. Am J Geriatr Cardiol 2004;13:267-272.
20. O'Brien T. Replacing the mercury sphygmomanometer: requires clinicians to demand better automated devices. BMJ 2000;320:815-816.
21. Parati G, Kilama MO, Faini A, et al. Blood pressure measurement device. A new solar-powered blood pressure measuring device for low-resource settings. Hypertension 2010;56:1047-1056.
22. Bur A, Herkner H, Vlcek M, et al. Classification of BP levels by ambulatory BP in hypertension. Hypertension 2002;40:817-822.
23. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011;378:1219-1230.
24. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375:181-183.
25. International Diabetes Federation (IDF). Consensus worldwide definition of the metabolic syndrome. Worldwide definition for use in clinical practice. Brussels: IDF. http://www.idf.org (accessed 20 October 2011).
26. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
27. Kaplan NM. Editorial. The choice or thiazide diuretics. Why chlorthalidone may replace hydrochlorothiazide. Hypertension 2009;54:951-953.
28. Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Is there a verdict yet? Hypertension 2011;57:665-666.
29. Dorsch MP, Gillespie BW, Erickson ST, et al. Chlorthalidone reduced cardiovascular events compared with hydrochlorothiazide. A retrospective cohort analysis. Hypertension 2011;57:689-694.
30. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-1124.
31. Barnett AH, Bain SC, Bouter P, et al. Angiotensin receptor blockade versus converting - enzyme inhibition in Type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
32. Pfeffer MA, McMurray JJ, Velazquez AJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-1906.
33. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
34. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951.
35. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan in the development of diabetic nephropathy in patients with diabetic nephropathy. N Engl J Med 2001;345:870-878.
36. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood- pressure lowering regimen among 6105 individuals with previous stroke or transient stroke. Lancet 2001; 358: 1033-1104.
37. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and mortality after stroke eprosartan compared compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36(6):1218-1226.
38. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
39. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenburg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
40. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
41. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in Type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1661-1671.
42. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372(9644):1174-1183.
43. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodopine or hydrochlothazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
44. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:2417-2428.
45. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent strokes and cardiovascular events. N Engl J Med 2008;359:1225-1237.
46. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.
47. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
48. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of high blood pressure in blacks consensus statement. Hypertension 2010;56:780-800.
49. Connor J, Rafter N, Rodgers A. Do fixed combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004;82:935-939.
50. Kaplan W, Laing R. Fixed drug combinations as an innovative delivery mechanism. In: Priority Medicines for Europe and the World. A Public Health Approach to Innovation. Geneva: World Health Organization, 2004.
51. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
52. Neal B, Chapman N, Patel A. Managing the global burden of cardiovascular disease. Eur Heart J 2002;4(F):F2-F6.
53. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002.
54. Reddy KS. The preventive polypill-much promise, insufficient evidence. N Engl J Med 2007;356:212.
55. van Zwieten PA. Interactions between antihypertensive agents and other drugs. European Society of Hypertension Scientific Newsletter 2003;4(17):1-2.
56. Egan A, Colman E. Weighing the benefits of high dose simvastatin against the risk of myopathy. N Engl J Med 2011;365:285-287.
57. Herbert CJ, Vidt DG. Hypertensive crisis. Prim Care 2008;35:478-487.
58. Handler J. Hypertensive urgency. J Clin Hypertens 2006;8:61-64.
59. South African Medical Association, Neurological Association of South Africa Stroke Working Group. Stroke therapy clinical guideline. S Afr Med J 2000;90:276-306.
60. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2007;2005:839-845.
61. Chapman N, Dobson J, Wilson S, et al. Effect of spironalactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845.
62. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation 2005;112:3562-3568.
63. Seedat YK. Diabetes mellitus in South African Indians. In: Mohan V, Rao GHD, eds. Type 2 Diabetes South Asians: Epidemiology, Risk Factors and Prevention. New Delhi: Jaypee Brothers, 2007;40-44.
64. Seedat YK. Varying responses to hypotensive agents in difference racial groups, black versus white differences. J Hypertens 1989;7:S15-S18.
65. Brewster LM, van Montfrans GA. Kleijnen systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004;141:614-627.
66. Sinaiko AR. Hypertension in children. N Engl J Med 1996;335:1968-1973.
67. National Heart, Lung and Blood Institute. Task force on blood pressure control in children. Bethesda, Maryland: National Heart, Lung and Blood Institute, 1987;79:1-25.
68. Seaberg EC, Munoz A, Lu M, et al. Association between highly active anti-retroviral therapy in a large cohort of men followed from 1984 to 2003. AIDS 2005;19:953-960.
69. Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78:143-153.
70. De Maat M, Ekhart GC, Huitema ADR, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003;44:223-282.
71. Seedat YK, Mayet FGH, Gouws E. Risk factors for coronary heart disease in the white community of Durban. S Afr Med J 1994;84:257-262.
72. Mollentze WF, Moore AJ, Steyn AF, et al. Coronary heart disease risk factors in a rural and urban Orange Free State black population. S Afr Med J 1995;85:90-96.
73. Molitch ME, DeFronzo RA, Franz MJ, et al. Diabetic nephropathy. Diabetes Care 2003;26:S94-99.
74. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-998.
75. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes. Lancet 1998;352:837-853.
76. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
77. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
78. Ruggenenti P, Lauria G, Iliev IP, et al. Effects of mandipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and mandipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58:776-783.
79. Morar N, Seedat YK, Naidoo DV, Desai DK. Ambulatory blood pressure and risk factors for coronary heart disease in black and Indian medical students. J Cardiovasc Risk 1998;5:313-318.
80. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004;22:1453-1458.
81. Edwards R, Unwin N, Mugusi F, et al. Hypertension prevalence and care in an urban and rural area of Tanzania. J Hypertens 2000;18:145-152.